Original title: Multiple domestic new crown drugs entering clinical trials are expected to become a “new weapon” in the fight against the epidemic
Xinhua News Agency, Beijing, November 19 (Reporters Dong Ruifeng and Xu Penghang) The reporter learned from the State Council’s Joint Prevention and Control Mechanism Scientific Research Team that my country’s self-developed new crown drugs have completed phase III clinical trials and are applying for conditional listing. In addition, a number of drugs have carried out phase III clinical trials at home and abroad, and currently show positive effects.
From the hundreds of antibodies isolated from the blood of convalescent patients, 2 strains of antibodies with high activity and strong complementarity were screened-the new coronavirus antibody combination drug BRII developed by Tsinghua University, Shenzhen Third People’s Hospital and Tengsheng Biopharmaceutical team -196/BRII-198, has recently completed a foreign phase III clinical trial, and has been urgently called by relevant departments to provide clinical treatment for more than 800 cases of infection in China.
According to Zhang Linqi, a professor at the School of Medicine of Tsinghua University, foreign phase III clinical trial data show that the antibody combination drug can reduce severe illness and mortality by 78%, and it still maintains activity against the new coronavirus variant. The drug has already submitted a rolling conditional marketing application to the National Food and Drug Administration in October, and an emergency use authorization application has also been submitted to the US Food and Drug Administration.
The neutralizing antibody JS016, jointly developed by the Institute of Microbiology of the Chinese Academy of Sciences and Shanghai Junshi Biotechnology, has also completed the international multi-center phase II clinical trial in November, and the current data show that it has achieved positive effects.
“We are cooperating with international pharmaceutical companies. So far, JS016 has been authorized for emergency use in 15 countries around the world, and more than 500,000 doses of drugs have been distributed globally.” Clinical patients of new coronary pneumonia are sympathetic to the medication, and the drug is currently being actively promoted in phase III clinical trials.
According to another report, the new generation of androgen receptor antagonist prokruamide of Suzhou Kaifeng Pharmaceutical and Azivudine of Henan Normal University are carrying out phase III clinical trials at home and abroad, and the neutralizing antibody BGB of Peking University and Beijing Danxu -DXP-604 and FB2001 and VV116 of Shanghai Institute of Materia Medica, Chinese Academy of Sciences are also in the development process.
According to the person in charge of the State Council’s Joint Prevention and Control Mechanism Scientific Research Team, the current research and development of new crown drugs is mainly carried out on three technical routes: blocking viruses from entering cells, inhibiting virus replication, and regulating the human immune system. my country has deployed these technical routes.
The State Council’s Joint Prevention and Control Mechanism Scientific Research Team, which is composed of the Ministry of Science and Technology, the National Health Commission, the Ministry of Industry and Information Technology, the National Development and Reform Commission, the State Food and Drug Administration, and the State Administration of Traditional Chinese Medicine. Since its establishment on the 16th, a national team of superior experts has been organized to fully promote the research and development of effective drugs and treatment technologies.
.